The story of copyright's flagship drug presents a nuanced case for stakeholders in the pharmaceutical sector. While initially a tremendous success, creating billions, the exclusivity expiration and the subsequent flood of off-brand versions have considerably impacted earnings. This raises questions about the future profitability of similar therapeu